1. Prognostic Significance of MTOR Pathway Component Expression in Neuroendocrine Tumors
   Zhi Rong Qian et al, 2013, Journal of Clinical Oncology CrossRef
2. Precision medicine in gastroenteropancreatic neuroendocrine neoplasms: Where are we in 2023?
   Nicola Fazio et al, 2023, Best Practice & Research Clinical Endocrinology & Metabolism CrossRef
3. Predictive factors of response to mTOR inhibitors in neuroendocrine tumours
   Maria Chiara Zatelli et al, 2016, Endocrine-Related Cancer CrossRef
4. Neuroendocrine Tumors of the Lung Other Than Small Cell Lung Cancer
   Krista Noonan et al, 2018, IASLC Thoracic Oncology CrossRef
5. Systemic treatment for lung carcinoids: from bench to bedside
   Mariangela Torniai et al, 2019, Clinical and Translational Medicine CrossRef
6. Targeted therapies for small cell lung cancer: Where do we stand?
   Alexandre Arcaro, 2015, Critical Reviews in Oncology/Hematology CrossRef
7. Antigene MYCN Silencing by BGA002 Inhibits SCLC Progression Blocking mTOR Pathway and Overcomes Multidrug Resistance
   Sonia Bortolotti et al, 2023, Cancers CrossRef
8. Expression of mTOR in normal and pathological conditions
   A Marques-Ramos et al, 2023, Molecular Cancer CrossRef
9. Interferon alpha and rapamycin inhibit the growth of carcinoid and medullary thyroid cancer in vitro
   Ewelina Motylewska et al, 2014, Pharmacological Reports CrossRef
10. Phosphatidylinositol-3-kinase α catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours
    ALESSANDRA CAPODANNO et al, 2012, Oncology Reports CrossRef
11. Akt as a potential prognostic marker in neuroendocrine tumors: a possibility?
    Angela Hague et al, 2016, International Journal of Endocrine Oncology CrossRef
12. Neuroendocrine Tumor of Lung and Mediastinum: the Updated Pathological Diagnosis and Treatment
    Yasushi Goto et al, 2019, Haigan CrossRef
13. Distinct subcellular localization of E-cadherin between epithelioid angiomyolipoma and triphasic angiomyolipoma: A preliminary case-control study
    Xin-Gang Bi et al, 2017, Oncology Letters CrossRef
14. Renal epithelioid angiomyolipoma with malignant features: Histological evaluation and novel immunohistochemical findings
    Sachiko Konosu‐Fukaya et al, 2014, Pathology International CrossRef
15. Pulmonary Large-Cell Neuroendocrine Carcinoma: Therapeutic Challenges and Opportunities
    Georgios Ioannidis, 2020, Forum of Clinical Oncology CrossRef
16. Expression of the phosphorylated variant of the AKT1-kinase (p-AKT1) in well-differentiated pancreatic neuroendocrine tumors: immunohistochemical evaluation
    V. V. Delektorskaya et al, 2018, Almanac of Clinical Medicine CrossRef
17. The Epidemiology of Neuroendocrine Tumors in Taiwan: A Nation-Wide Cancer Registry-Based Study
    Hui-Jen Tsai et al, 2013, PLoS ONE CrossRef
18. PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup
    Lei Wang et al, 2014, PLoS ONE CrossRef
19. Therapeutic Biomarkers in Lung Neuroendocrine Neoplasia
    Luisella Righi et al, 2014, Endocrine Pathology CrossRef
20. Current understanding of pathogenetic mechanisms in neuroendocrine neoplasms
    Roberta Modica et al, 2024, Expert Review of Endocrinology & Metabolism CrossRef